Chronic pain frequently co-occurs with major depressive disorder but the mechanisms are poorly understood. We investigated the contribution of indoleamine 2,3-dioxygenase-1 (IDO1), a rate-limiting enzyme in the conversion of tryptophan to neurotoxic metabolites, to this comorbidity using the spared nerve injury (SNI) model of neuropathic pain in mice.
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SNI resulted in unilateral mechanical allodynia, reduced social interaction, and increased immobility in the forced swim test without changes in locomotor activity. These findings indicate SNI-induced pain and comorbid depression-like behavior. These behavioral responses were accompanied by increases in plasma kynurenine/tryptophan ratios and increased expression of Ido1 and Il1b mRNA in the liver. Interestingly, SNI did not induce detectable changes in spinal cord or brain Ido1 mRNA levels. SNI was associated with spinal cord inflammatory activity as evidenced by increased Il1b mRNA expression. The SNI-induced increase of liver Ido1and Il1b mRNA was abrogated by intrathecal administration of the IL-1 inhibitor IL-1RA. Intrathecal IL-1RA also inhibited both mechanical allodynia and depression-like behavior. We also show that Ido1 is required for the development of depression-like behavior because Ido1 À/À mice do not develop increased immobility in the forced swim test or decreased social exploration in response to SNI. Mechanical allodynia was similar in WT and Ido1 À/À mice.
In conclusion, our findings show for the first time that neuropathic pain is associated with an increase of Ido1 in liver, but not brain, downstream of spinal cord IL-1b signaling and that Ido1 mediates comorbid depression. Moreover, comorbidity of neuropathic pain and depression are only partially mediated by a common mechanism because mechanical hyperalgesia develops independently of Ido1.
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Introduction
Pain and depression frequently occur together. Clinically, more than 50% of patients suffering from chronic pain also experience symptoms of depression (Arnow et al., 2006; Bair et al., 2003) . Specifically, patients with multiple pain symptoms (e.g., back pain, headache, abdominal pain, chest pain and facial pain) are 3-5 times more likely to be depressed than individuals without pain (Bair et al., 2003; Magni et al., 1993; Von Korff et al., 1988) .
Conversely, depressed patients are more likely to develop low back pain, neck-shoulder pain, and musculoskeletal symptoms than non-depressed individuals (Arnow et al., 2006; Trivedi, 2004) . Comorbid chronic pain and depression are difficult to treat, partially because of a lack of knowledge on the commonalities and specificities of the underlying mechanisms.
In models of persistent peripheral inflammation or in models of neuropathic pain, inflammatory cytokines produced by spinal cord microglia and astrocytes contribute to the pain response (Clark et al., 2010; Ikeda et al., 2012; Eijkelkamp et al., 2010) . Inflammatory cytokines produced in the brain mediate depression-like behavior (e.g. increased immobility time in the forced swim test) induced by systemic administration of lipopolysaccharide
